Novo Nordisk AS’s investigational GLP-1 agonist semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SUSTAIN-6 cardiovascular outcomes trial, which will strengthen its new drug application for the therapy and supplement future negotiations with pricing regulators.
The full data from the SUSTAIN-6 non-inferiority study were presented on Sept